Incruse Ellipta umeclidinium bromide regulatory update

GlaxoSmithKline said Canada approved Incruse Ellipta umeclidinium bromide for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obst...